Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) EBT Margin (2020 - 2025)

Roivant Sciences (ROIV) has disclosed EBT Margin for 6 consecutive years, with 14525.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin fell 1192521.0% year-over-year to 14525.71%, compared with a TTM value of 16606.06% through Dec 2025, down 3836750.0%, and an annual FY2025 reading of 2346.02%, down 1630945.0% over the prior year.
  • EBT Margin was 14525.71% for Q4 2025 at Roivant Sciences, down from 10123.74% in the prior quarter.
  • Across five years, EBT Margin topped out at 13876.0% in Q4 2023 and bottomed at 14525.71% in Q4 2025.
  • Average EBT Margin over 5 years is 3527.14%, with a median of 2503.44% recorded in 2022.
  • The sharpest move saw EBT Margin soared 1611665bps in 2023, then tumbled -1647650bps in 2024.
  • Year by year, EBT Margin stood at 664.41% in 2021, then tumbled by -237bps to 2240.66% in 2022, then skyrocketed by 719bps to 13876.0% in 2023, then plummeted by -119bps to 2600.5% in 2024, then plummeted by -459bps to 14525.71% in 2025.
  • Business Quant data shows EBT Margin for ROIV at 14525.71% in Q4 2025, 10123.74% in Q3 2025, and 12408.39% in Q2 2025.